In an era where psychedelic-assisted therapy is transitioning from a counterculture curiosity to a potential cornerstone of modern psychiatry, the scientific community has reached a pivotal juncture. As substances like MDMA and psilocybin gain unprecedented traction as potential treatments for debilitating mental health disorders, a major international study led by researchers at McGill University, Imperial College London, and the University of Exeter has introduced a new framework designed to overhaul the rigor and reliability of clinical research in the field.
For years, the burgeoning field of psychedelic science has grappled with a fundamental methodological challenge: the "set and setting" phenomenon. While the phrase has been a staple of psychedelic culture since the 1960s, its integration into the rigid, sterilized world of clinical trials has been remarkably inconsistent. Up to now, psychedelic clinical trials have suffered from what is widely acknowledged as a critical flaw—the failure to properly account for how a person’s internal mindset (set) and their external physical and social surroundings (setting) influence the therapeutic effects of the drug.
This systemic gap has led to a fragmentation of data, where study results often appear inconsistent or difficult to replicate. Such variability has created significant hurdles for regulatory approval, as agencies struggle to discern whether a patient’s improvement is a result of the pharmacological agent itself, the environment in which it was administered, or a complex synergy between the two.
To resolve this ambiguity, an international coalition of scientists has developed the Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) guidelines. Published recently in the prestigious journal Nature Medicine, these guidelines are the result of a rigorous Delphi consensus study that brought together 89 leading experts from 17 countries. The multi-round debate culminated in a 30-item checklist that represents the first global agreement on which psychosocial factors have the greatest impact on a psychedelic experience.
"For decades, we’ve known that psychedelics don’t work in isolation. The person’s mindset, the therapy room, even the music playing all influence outcomes," said co-lead author Chloé Pronovost-Morgan, a researcher at McGill University and Imperial College London. "Two trials using the same psychedelic drug, at the same dose, can produce completely different results depending on the environment."
This approach fundamentally challenges the traditional paradigm of psychoactive drug research. In standard pharmaceutical trials, scientists typically strive to control, minimize, or entirely eliminate outside variables to isolate the specific effects of a molecule on the brain. However, the ReSPCT guidelines recognize that for psychedelics, context is not a "noise" to be filtered out, but a crucial component of the treatment itself that must be studied and reported directly.
Why guidelines matter
The introduction of these guidelines comes at a time of both high optimism and significant regulatory tension. By offering a standard framework for evaluating and reporting these variables, the ReSPCT guidelines aim to make trial outcomes more consistent and comparable across different global research sites. Without such a framework, comparing a study conducted in a clinical hospital setting in New York to one conducted in a more aesthetic, living-room-style environment in London becomes an exercise in guesswork.
Leor Roseman, a researcher from the University of Exeter and co-senior author of the study, emphasized that standardizing these variables is the only way to truly unlock the science behind these substances. "Having clear guidelines for contextual considerations is essential to understand the effects of psychedelics and how they work differently from other psychiatric medications," Roseman stated. "Our guidelines will also help in replicating results and understanding the true therapeutic potential of psychedelics."
Unlike traditional antidepressants, such as SSRIs, which are generally expected to function regardless of the room’s lighting or the patient’s rapport with their doctor during the moment of ingestion, psychedelics act as "non-specific amplifiers." They tend to heighten the user’s awareness of their internal and external world. If the environment is clinical and cold, the experience may turn distressing; if it is supportive and intentional, the therapeutic breakthrough may be profound.
The lack of standardized reporting for these nuances has already had tangible consequences for the industry. Chloé Pronovost-Morgan pointed to a major recent setback: the U.S. Food and Drug Administration’s (FDA) decision to reject MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD). In its evaluation, the FDA cited inconsistent reporting and methodological concerns across trials as key reasons for the decision. The agency noted that without clear data on how the psychological interventions and the physical settings influenced the drug’s efficacy, it was difficult to establish a clear safety and efficacy profile that would meet the "gold standard" required for federal approval.
The ReSPCT guidelines are designed to prevent such regulatory roadblocks in the future. By providing a 30-item checklist, the researchers are giving scientists a roadmap to document everything from the duration of preparatory therapy sessions to the specific types of music played during the dosing session, and even the physical comfort of the room. This level of detail allows regulators and other scientists to see the "full picture" of the intervention.
"There is immense public interest in psychedelic therapies, particularly for individuals suffering from debilitating mental health conditions like PTSD, depression and anxiety, which have not responded to existing treatments," said co-senior author Kyle Greenway, Assistant Professor in McGill’s Division of Social and Transcultural Psychiatry and a researcher at the Lady Davis Institute for Medical Research.
Greenway highlighted the human stakes involved in this research. For millions of patients who have found little relief in traditional pharmacy-based approaches, psychedelics represent a "beacon of hope." However, that hope can only be realized if the science is beyond reproach. "Our guidelines offer a new gold standard for psychedelic research, helping bring these treatments to those who need them most," Greenway added.
The development of the ReSPCT guidelines involved a diverse range of perspectives, ensuring that the checklist is applicable across different cultural and clinical contexts. The 89 experts involved in the Delphi study included psychiatrists, psychologists, pharmacologists, and indigenous practitioners, reflecting the multifaceted nature of psychedelic use. The 17-country involvement ensures that the guidelines are not just a Western-centric model but a global standard that can be utilized in diverse healthcare systems.
The items in the checklist cover three primary domains: the "set" (the participant’s internal state, expectations, and psychological preparation), the "setting" (the physical environment, the presence of music, and the aesthetic qualities of the space), and the "provider" (the characteristics, training, and behavior of the therapists or guides present during the session). By systematically reporting these factors, researchers can begin to identify which specific elements of the "setting" contribute most to positive clinical outcomes.
For example, if multiple trials across the world use the ReSPCT guidelines and all find that a specific type of musical intervention or a specific duration of "integration therapy" following the dose leads to better long-term recovery from depression, the medical community can move toward a more optimized, evidence-based protocol for delivery.
The research team is not stopping at the publication of the guidelines. They are already moving toward the implementation phase to ensure these standards are adopted by the global scientific community. A three-day workshop is scheduled for October, funded by McGill University’s Healthy Brains, Healthy Lives (HBHL) initiative. This event will gather leading experts in psychedelics, neuroscience, and clinical trial design to discuss the practicalities of integrating the ReSPCT guidelines into both ongoing research and future clinical practice.
The workshop aims to bridge the gap between theoretical guidelines and the reality of the lab and clinic. It will address how to train researchers to use the checklist effectively and how to encourage journals and regulatory bodies to require these standards as a prerequisite for publication and drug filing.
As the "psychedelic renaissance" continues to accelerate, the move toward standardization marks a maturing of the field. By acknowledging that the mind and the environment are just as important as the molecule, the researchers at McGill, Imperial, and Exeter are providing the necessary infrastructure to turn experimental treatments into validated medical therapies. The ReSPCT guidelines represent a significant step toward a future where mental health treatments are not just about chemical balance, but about the holistic experience of the patient.
